1. Home
  2. INAB vs ALAR Comparison

INAB vs ALAR Comparison

Compare INAB & ALAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.75

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

SELL

Current Price

$0.97

Market Cap

10.7M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
INAB
ALAR
Founded
2016
2013
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.7M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
INAB
ALAR
Price
$0.75
$0.97
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$7.00
★ $16.00
AVG Volume (30 Days)
★ 69.2K
20.9K
Earning Date
11-05-2026
12-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$24.89
Revenue Next Year
N/A
$26.13
P/E Ratio
★ N/A
$44.31
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$1.00
52 Week High
$2.73
$12.00

Technical Indicators

Market Signals
Indicator
INAB
ALAR
Relative Strength Index (RSI) 32.88 26.94
Support Level N/A N/A
Resistance Level $1.50 $1.59
Average True Range (ATR) 0.08 0.09
MACD -0.01 -0.01
Stochastic Oscillator 9.62 2.45

Price Performance

Historical Comparison
INAB
ALAR

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

Share on Social Networks: